The Quiet AI Takeover of the Mundane Economy

I often get asked where all the AI hype is actually going if we look past the obvious hyperscalers. The truth is, the most fascinating technological shifts right now are happening in the boring, unsexy layers of our economy's infrastructure.

I'm told that the recent partnership expansion between Fidelity National Information Services (FIS.US) and Anthropic is a perfect example of this quiet revolution. FIS is a massive financial technology provider, and they are now plugging Anthropic's Mythos 5 frontier AI model directly into their core software infrastructure as an added security layer. This matters because it signals a fundamental transition where generative AI moves from consumer novelty to mission-critical bank security.

And yet, powering this transition requires an immaculate semiconductor supply chain. Onto Innovation (ONTO.US) sits right in this critical path, providing process control solutions to major chipmakers. They recently partnered with Rigaku to advance next-generation inspection tools. You would think their stock would be soaring on the AI chip boom. Instead, shares have pulled back roughly 25% over the past month. The truth, as usual, is more complicated: building the physical tools that enable artificial intelligence is a brutally cyclical and demanding business.

This collision between software ambition and physical reality is playing out across the biotech landscape as well. Certara (CERT.US) is trying to speed up drug discovery by hooking up its biosimulation software with NVIDIA's BioNeMo toolkit and snapping up companies like Chemaxon. It is an elegant software solution to a biological problem. But in biotech, software only gets you so far before you hit the FDA regulatory wall.

Just look at the ongoing drama over at Sarepta Therapeutics (SRPT.US). The gene therapy developer recently shook up its leadership, bringing in former AbbVie executive Michael Severino to replace its retiring CEO. Wall Street analysts remain heavily skeptical, recently slapping the stock with a sell rating. A new boss does not change the fundamental challenge of delivering undeniable efficacy data for their Duchenne muscular dystrophy treatment later this year. Good luck with that.

The gene therapy space is notoriously expensive to navigate. REGENXBIO (RGNX.US) just had to tap the public markets with an underwritten offering to shore up cash, though they did manage to unlock a USD 100 million milestone payment after dosing the first patient in a key diabetic retinopathy trial. Meanwhile, Novavax (NVAX.US) is still fighting to prove its relevance in the post-pandemic era. They have inked a licensing deal with Pfizer and are making the rounds at global healthcare conferences, but changing the market's perception of a legacy COVID vaccine maker is a steep climb.

If you think biotech is hard, let us talk about hardware. I have always been fascinated by the promise of next-generation mobility, but the capital destruction in this space is staggering. Whoops! BETA Technologies (BETA.US), the electric aviation darling, has seen its stock plunge over 30% year-to-date. They recently showed off their new MV250 aircraft at Farnborough, but getting a flying car certified and manufactured at scale is a money-melting exercise. The same goes for terrestrial autonomy. Micropolis AI Robotics (MCRP.US) just signed a USD 9.3 million commercial agreement for their autonomous mobile robots. Did the market care? Barely. The stock remains trapped near its 52-week lows, down significantly over the past year.

When the appetite for deep-tech cash-burners dries up, capital predictably flows to safer shores. I have noticed income-focused funds like the Amplify CWP International Enhanced Dividend Income ETF (IDVO.US) quietly absorbing investor cash by offering a dividend yield north of 5%. Compare that to the painful reality of former growth darlings like TAL Education Group (TAL.US). As the Chinese smart learning company prepares for its fiscal 2027 Q1 earnings, its own CFO recently dumped over USD 600,000 worth of internal shares. Not exactly a ringing endorsement of future prospects.

My view is that we have entered an era of profound impatience. Whether you are baking AI into bank infrastructure or trying to build autonomous flying machines, the market in 2026 demands execution over pure narrative. The grace period for building the future is officially over.

This article does not constitute investment advice.